Advertisement

Clinical Rheumatology

, Volume 27, Issue 1, pp 67–76 | Cite as

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence

  • Gerald GartlehnerEmail author
  • Richard A. Hansen
  • Beth L. Jonas
  • Patricia Thieda
  • Kathleen N. Lohr
Original Article

Abstract

Biologics are an important therapeutic option for treating patients with juvenile idiopathic arthritis (JIA). In adults, they are associated with rare but severe adverse events such as serious infections and malignancies. We reviewed systematically the evidence on the efficacy and safety of biologics for the treatment of JIA. We searched electronic databases up to August 2006. We limited evidence to prospective studies for efficacy but included retrospective observational evidence for safety. Outcomes of interest were clinical response, radiographic progression, quality of life, and adverse events. One randomized controlled trial (RCT) and 11 uncontrolled prospective studies provided data on efficacy; three additional studies assessed safety. The only RCT and six uncontrolled trials support the general efficacy of etanercept for the treatment of JIA. Internal and external validity of these studies are limited. The evidence on other biologic agents such as adalimumab, abatacept, anakinra, infliximab, rituximab, and tocilizumab is sparse or entirely missing. Because of the lack of sound long-term safety data, evidence is insufficient to draw firm conclusions about the balance of risks and benefits of any biologic agent for the treatment of JIA. Clinicians have to be aware of the lack of evidence supporting a long-term net benefit when considering biologics for patients with JIA.

Keywords

Biologics Juvenile idiopathic arthritis Systematic review Targeted immune modulators 

Notes

Acknowledgments

We would like to thank Timothy S. Carey, MD, MPH for helpful comments on an earlier version of this manuscript and Laura Morgan for data management.

This study was funded by a subcontract of the Oregon Health and Science University to the Cecil C. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill. The funding source had no role in the collection, analysis, and interpretation of the data.

Competing interests

None of the authors have any competing interests with the content of this manuscript.

Authors’ contributions

GG conducted data analysis and drafted the manuscript. RAH, BJL, PT, and KNL conducted data analysis and contributed to the manuscript. All authors read and approved the final manuscript.

References

  1. 1.
    Manners PJ, Bower C (2002) Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 29(7):1520–1530PubMedGoogle Scholar
  2. 2.
    Ravelli A, Martini A (2007) Juvenile idiopathic arthritis. Lancet 369(9563):767–778PubMedCrossRefGoogle Scholar
  3. 3.
    Andersson Gare B (1999) Juvenile arthritis—who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 17(3):367–374PubMedGoogle Scholar
  4. 4.
    Newacheck PW, Taylor WR (1992) Childhood chronic illness: prevalence, severity, and impact. Am J Public Health 82(3):364–371PubMedCrossRefGoogle Scholar
  5. 5.
    Thompson SD, Moroldo MB, Guyer L et al (2004) A genome-wide scan for juvenile rheumatoid arthritis in affected sibpair families provides evidence of linkage. Arthritis Rheum 50(9):2920–2930PubMedCrossRefGoogle Scholar
  6. 6.
    Petty RE, Southwood TR, Manners P et al (2004) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31(2):390–392PubMedGoogle Scholar
  7. 7.
    Hashkes PJ, Laxer RM (2005) Medical treatment of juvenile idiopathic arthritis. JAMA 294(13):1671–1684PubMedCrossRefGoogle Scholar
  8. 8.
    Minden K, Kiessling U, Listing J et al (2000) Prognosis of patients with juvenile chronic arthritis and juvenile spondyloarthropathy. J Rheumatol 27(9):2256–2263PubMedGoogle Scholar
  9. 9.
    Wilkinson N, Jackson G, Gardner-Medwin J (2003) Biologic therapies for juvenile arthritis. Arch Dis Child 88(3):186–191PubMedCrossRefGoogle Scholar
  10. 10.
    Gartlehner G, Hansen RA, Jonas BL et al (2006) The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J Rheumatol 33(12):2398–2408PubMedGoogle Scholar
  11. 11.
    Lovell DJ (2004) Preliminary data from a study of adalimumab in children with JIA. Arthritis Rheum 50:S436 (Suppl)Google Scholar
  12. 12.
    Irigoyen PI, Olson J, Hom C (2004) Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 50:S437 (Suppl)Google Scholar
  13. 13.
    Reiff A (2005) The use of anakinra in juvenile arthritis. Curr Rheumatol Rep 7(6):434–440PubMedCrossRefGoogle Scholar
  14. 14.
    Lovell DJ, Ruperto N, Cuttica R (2004) Randomized trial of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis poster. American College of Rheumatology 68th Annual Scientific Meeting. San Antonio, TXGoogle Scholar
  15. 15.
    Gartlehner G, Hansen RA, Thieda P et al (2005) Drug class review on targeted immune modulators. Drug Effectiveness Review Project, PortlandGoogle Scholar
  16. 16.
    Fox DM (2005) Evidence of evidence-based health policy: the politics of systematic reviews in coverage decisions. Health Aff (Millwood) 24(1):114–122CrossRefGoogle Scholar
  17. 17.
    Giannini EH, Ruperto N, Ravelli A et al (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40(7):1202–1209PubMedGoogle Scholar
  18. 18.
    Giannini EH, Lovell DJ, Felson DT et al (1994) Preliminary core set of outcome variables for use in JRA clinical trials. Arthritis Rheum 37:S428 (Suppl)CrossRefGoogle Scholar
  19. 19.
    Harris RP, Helfand M, Woolf SH et al (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20(3):21–35PubMedCrossRefGoogle Scholar
  20. 20.
    Anonymous (2001) Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. CRD report number 4, 2nd edn. CRD, YorkGoogle Scholar
  21. 21.
    Deeks JJ, Dinnes J, D’Amico R et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7(27):iii–x, 1–173PubMedGoogle Scholar
  22. 22.
    ClinicalTrails.gov. (2007) BMS-188667 in children and adolescents with juvenile rheumatoid arthritis. http://wwwclinicaltrialsgov/ct/show/NCT00095173?order=16. Cited 5 May 2007
  23. 23.
    Ruperto N (2006) 2006 EULAR meeting proceedings. 48-week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JR). Ann Rheum Dis 65:OP0007 (Suppl)Google Scholar
  24. 24.
    Andrias R, Porras O, Rudge S (2002) Preliminary data from a study of kineret (anakinra) in children with juvenile rheumatoid arthritis abstract. Arthritis Rheum 46:496 (Suppl)Google Scholar
  25. 25.
    Ilowite NT, Reiff A, Rudge S et al (2006) Abstract 723: A randomized, multi-center, blinded, placebo-controlled study with an open-label run-in period to evaluate anakinra in polyarticular-course juvenile rheumatoid arthritis. American College of Rheumatology National Scientific MeetingGoogle Scholar
  26. 26.
    Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342(11):763–769PubMedCrossRefGoogle Scholar
  27. 27.
    Horneff G, Schmeling H, Biedermann T et al (2004) The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63(12):1638–1644PubMedCrossRefGoogle Scholar
  28. 28.
    Henrickson M, Reiff A (2004) Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 31(10):2055–2061PubMedGoogle Scholar
  29. 29.
    Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 61(2):171–173PubMedCrossRefGoogle Scholar
  30. 30.
    Quartier P, Taupin P, Bourdeaut F et al (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48(4):1093–1101PubMedCrossRefGoogle Scholar
  31. 31.
    Russo RA, Katsicas MM, Zelazko M (2002) Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol 20(5):723–726PubMedGoogle Scholar
  32. 32.
    Lahdenne P, Vahasalo P, Honkanen V (2003) Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62(3):245–247PubMedCrossRefGoogle Scholar
  33. 33.
    CDER/FDA (1999) Food and drug administration center for biologics evaluation and research, statistical review and evaluation of BLA #98-1296. http://www.fda.gov/cder/biologics/review/etanimm052799r2.pdf
  34. 34.
    Lovell DJ, Giannini EH, Reiff A et al (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48(1):218–226PubMedCrossRefGoogle Scholar
  35. 35.
    Lovell DJ, Reiff A, Jones OY et al (2006) Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 54(6):1987–1994PubMedCrossRefGoogle Scholar
  36. 36.
    Tauber T, Turetz J, Barash J et al (2006) Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS 10(1):26–29PubMedCrossRefGoogle Scholar
  37. 37.
    Gerloni V, Pontikaki I, Gattinara M et al (2005) Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 52(2):548–553PubMedCrossRefGoogle Scholar
  38. 38.
    Katsicas MM, Russo RA (2005) Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol 23(4):545–548PubMedGoogle Scholar
  39. 39.
    Masatlioglu S, Gogus F, Cevrigen D (2002) Infliximab in the treatment of refractory juvenile idiopathic arthritis. Arthritis Rheum 46(9):S481Google Scholar
  40. 40.
    Scarazatti M, Beltramelli M, Dell’Era L (2001) Infliximab in juvenile idiopathis arthrits abstract. Ann Rheum Dis 60:ii17–ii53 (abstract P180)Google Scholar
  41. 41.
    Honkanen V, Tynjala P, Vahasalo P (2002) Infliximab in juvenile arthritis: 1-year follow up abstract. Arthritis Rheum 46:1272 (Suppl)Google Scholar
  42. 42.
    Woo P, Wilkinson N, Prieur AM et al (2005) Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7(6):R1281–R1288PubMedCrossRefGoogle Scholar
  43. 43.
    Yokota S, Miyamae T, Imagawa T et al (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52(3):818–825PubMedCrossRefGoogle Scholar
  44. 44.
    Yokota S, Imagawa T, Mori M et al (2006) Abstract 722: Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade—results from a tocilizumab sJIA phase III clinical trial. American College of Rheumatology National Scientific MeetingsGoogle Scholar
  45. 45.
    Genovese MC, Bathon JM, Martin RW et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46(6):1443–1450PubMedCrossRefGoogle Scholar
  46. 46.
    Higgins G, Jones K, Rennebohm R (2000) Variable response of systemic juvenile rheumatoid arthritis to etanercept abstract. Arthritis Rheum 43:S257 (Suppl)Google Scholar
  47. 47.
    Kimura Y, Pinho P, Walco G et al (2005) Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 32(5):935–942PubMedGoogle Scholar
  48. 48.
    Kietz DA, Pepmueller PH, Moore TL (2001) Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 28(2):360–362PubMedGoogle Scholar
  49. 49.
    Haapasaari J, Kautiainen H, Hannula S et al (2002) Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol 20(6):867–870PubMedGoogle Scholar
  50. 50.
    Schmeling H, Mathony K, John V et al (2001) A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: A pilot study. Ann Rheum Dis 60(4):410–412PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2007

Authors and Affiliations

  • Gerald Gartlehner
    • 1
    Email author
  • Richard A. Hansen
    • 2
  • Beth L. Jonas
    • 3
  • Patricia Thieda
    • 4
  • Kathleen N. Lohr
    • 5
  1. 1.Ludwig Boltzmann Institute for Health Technology AssessmentsViennaAustria
  2. 2.School of Pharmacy, Division of Pharmaceutical Policy & Evaluative SciencesUniversity of North Carolina at Chapel HillChapel HillUSA
  3. 3.School of Medicine, Thurston Arthritis Research CenterUniversity of North Carolina at Chapel HillChapel HillUSA
  4. 4.Cecil G. Sheps Center for Health Services ResearchUniversity of North Carolina at Chapel HillChapel HillUSA
  5. 5.School of Public Health, Health Policy & AdministrationUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations